Where should HCPs position Synjardy in the treatment of T2D and its complications?

Document ID: PC-ZA-102139

16/05/2023

Author: Boehringer Ingelheim


Empagliflozin has demonstrated to be cost saving when added to standard of care in other countries but, what about South Africa? In the Budget Impact of Empagliflozin in the Treatment of Patients with T2D with eCVD in South Africa, Professor Jacques Snyman investigates Empagliflozin's financial impact on top of usual care and answers this and many others question.

123,000
Views

100k 340

Related content

 
PC-ZA-102139
Production date: May 2023